JP2014110814A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014110814A5 JP2014110814A5 JP2014057616A JP2014057616A JP2014110814A5 JP 2014110814 A5 JP2014110814 A5 JP 2014110814A5 JP 2014057616 A JP2014057616 A JP 2014057616A JP 2014057616 A JP2014057616 A JP 2014057616A JP 2014110814 A5 JP2014110814 A5 JP 2014110814A5
- Authority
- JP
- Japan
- Prior art keywords
- human
- mouse
- gene
- gene segment
- cell
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 108090000623 proteins and genes Proteins 0.000 claims 89
- 210000004027 cell Anatomy 0.000 claims 23
- 238000003780 insertion Methods 0.000 claims 14
- 230000037431 insertion Effects 0.000 claims 14
- 101000998953 Homo sapiens Immunoglobulin heavy variable 1-2 Proteins 0.000 claims 7
- 102100036887 Immunoglobulin heavy variable 1-2 Human genes 0.000 claims 7
- 108091028043 Nucleic acid sequence Proteins 0.000 claims 7
- 239000000427 antigen Substances 0.000 claims 7
- 102000036639 antigens Human genes 0.000 claims 7
- 108091007433 antigens Proteins 0.000 claims 7
- 150000007523 nucleic acids Chemical group 0.000 claims 7
- 210000003719 b-lymphocyte Anatomy 0.000 claims 6
- 238000000034 method Methods 0.000 claims 5
- 210000004408 hybridoma Anatomy 0.000 claims 4
- 102000004169 proteins and genes Human genes 0.000 claims 4
- 238000011144 upstream manufacturing Methods 0.000 claims 4
- 210000001161 mammalian embryo Anatomy 0.000 claims 3
- 101710098119 Chaperonin GroEL 2 Proteins 0.000 claims 2
- 108020004414 DNA Proteins 0.000 claims 2
- 238000012258 culturing Methods 0.000 claims 2
- 210000001671 embryonic stem cell Anatomy 0.000 claims 2
- 230000003053 immunization Effects 0.000 claims 2
- 102000006496 Immunoglobulin Heavy Chains Human genes 0.000 claims 1
- 108010019476 Immunoglobulin Heavy Chains Proteins 0.000 claims 1
- 241000283984 Rodentia Species 0.000 claims 1
- 210000001185 bone marrow Anatomy 0.000 claims 1
- 230000000694 effects Effects 0.000 claims 1
- 238000002649 immunization Methods 0.000 claims 1
- 210000001165 lymph node Anatomy 0.000 claims 1
- 238000004519 manufacturing process Methods 0.000 claims 1
- 210000000952 spleen Anatomy 0.000 claims 1
- 210000001519 tissue Anatomy 0.000 claims 1
Applications Claiming Priority (6)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161446895P | 2011-02-25 | 2011-02-25 | |
| US61/446,895 | 2011-02-25 | ||
| US201161497650P | 2011-06-16 | 2011-06-16 | |
| US61/497,650 | 2011-06-16 | ||
| US201261595200P | 2012-02-06 | 2012-02-06 | |
| US61/595,200 | 2012-02-06 |
Related Parent Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550677A Division JP2014507137A (ja) | 2011-02-25 | 2012-02-24 | Ａｄａｍ６マウス |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015036588A Division JP2015107131A (ja) | 2011-02-25 | 2015-02-26 | Ａｄａｍ６マウス |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014110814A JP2014110814A (ja) | 2014-06-19 |
| JP2014110814A5 true JP2014110814A5 (enExample) | 2015-04-09 |
| JP5866127B2 JP5866127B2 (ja) | 2016-02-17 |
Family
ID=45998616
Family Applications (8)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550677A Pending JP2014507137A (ja) | 2011-02-25 | 2012-02-24 | Ａｄａｍ６マウス |
| JP2014057616A Active JP5866127B2 (ja) | 2011-02-25 | 2014-03-20 | Ａｄａｍ６マウス |
| JP2015036588A Withdrawn JP2015107131A (ja) | 2011-02-25 | 2015-02-26 | Ａｄａｍ６マウス |
| JP2016088848A Withdrawn JP2016135143A (ja) | 2011-02-25 | 2016-04-27 | Ａｄａｍ６マウス |
| JP2018107070A Withdrawn JP2018143250A (ja) | 2011-02-25 | 2018-06-04 | Ａｄａｍ６マウス |
| JP2019127562A Withdrawn JP2019187446A (ja) | 2011-02-25 | 2019-07-09 | Ａｄａｍ６マウス |
| JP2022029501A Pending JP2022071051A (ja) | 2011-02-25 | 2022-02-28 | Ａｄａｍ６マウス |
| JP2024212173A Pending JP2025032218A (ja) | 2011-02-25 | 2024-12-05 | Ａｄａｍ６マウス |
Family Applications Before (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2013550677A Pending JP2014507137A (ja) | 2011-02-25 | 2012-02-24 | Ａｄａｍ６マウス |
Family Applications After (6)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2015036588A Withdrawn JP2015107131A (ja) | 2011-02-25 | 2015-02-26 | Ａｄａｍ６マウス |
| JP2016088848A Withdrawn JP2016135143A (ja) | 2011-02-25 | 2016-04-27 | Ａｄａｍ６マウス |
| JP2018107070A Withdrawn JP2018143250A (ja) | 2011-02-25 | 2018-06-04 | Ａｄａｍ６マウス |
| JP2019127562A Withdrawn JP2019187446A (ja) | 2011-02-25 | 2019-07-09 | Ａｄａｍ６マウス |
| JP2022029501A Pending JP2022071051A (ja) | 2011-02-25 | 2022-02-28 | Ａｄａｍ６マウス |
| JP2024212173A Pending JP2025032218A (ja) | 2011-02-25 | 2024-12-05 | Ａｄａｍ６マウス |
Country Status (31)
| Country | Link |
|---|---|
| US (12) | US8642835B2 (enExample) |
| EP (7) | EP4067496B1 (enExample) |
| JP (8) | JP2014507137A (enExample) |
| KR (1) | KR101387377B1 (enExample) |
| CN (2) | CN105861548B (enExample) |
| AU (6) | AU2012243291B2 (enExample) |
| BR (1) | BR112013021771B1 (enExample) |
| CA (1) | CA2820824A1 (enExample) |
| CY (5) | CY1116301T1 (enExample) |
| DE (5) | DE14176593T1 (enExample) |
| DK (6) | DK2738259T3 (enExample) |
| ES (6) | ES2532487T3 (enExample) |
| FI (3) | FI2578688T4 (enExample) |
| HR (5) | HRP20230526T1 (enExample) |
| HU (5) | HUE024534T2 (enExample) |
| IL (4) | IL226727A (enExample) |
| IN (1) | IN2013CN07629A (enExample) |
| LT (4) | LT2738259T (enExample) |
| ME (3) | ME03732B (enExample) |
| MX (3) | MX375115B (enExample) |
| MY (1) | MY172713A (enExample) |
| NZ (2) | NZ731926A (enExample) |
| PL (5) | PL2738259T3 (enExample) |
| PT (5) | PT2738258T (enExample) |
| RS (5) | RS53880B1 (enExample) |
| RU (2) | RU2722373C2 (enExample) |
| SG (4) | SG10201913160QA (enExample) |
| SI (5) | SI2738258T2 (enExample) |
| SM (5) | SMT202300173T1 (enExample) |
| WO (1) | WO2012141798A1 (enExample) |
| ZA (1) | ZA201305998B (enExample) |
Families Citing this family (91)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US20050144655A1 (en) | 2000-10-31 | 2005-06-30 | Economides Aris N. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| USRE47770E1 (en) | 2002-07-18 | 2019-12-17 | Merus N.V. | Recombinant production of mixtures of antibodies |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| EP2395016A3 (en) | 2003-05-30 | 2012-12-19 | Merus B.V. | Design and use of paired variable regions of specific binding molecules |
| US20100069614A1 (en) | 2008-06-27 | 2010-03-18 | Merus B.V. | Antibody producing non-human mammals |
| EP4353819A3 (en) | 2004-07-22 | 2024-07-17 | Erasmus University Medical Center Rotterdam | Binding molecules |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| CN102638971B (zh) | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| US9445581B2 (en) | 2012-03-28 | 2016-09-20 | Kymab Limited | Animal models and therapeutic molecules |
| US9796788B2 (en) | 2010-02-08 | 2017-10-24 | Regeneron Pharmaceuticals, Inc. | Mice expressing a limited immunoglobulin light chain repertoire |
| US20130045492A1 (en) | 2010-02-08 | 2013-02-21 | Regeneron Pharmaceuticals, Inc. | Methods For Making Fully Human Bispecific Antibodies Using A Common Light Chain |
| US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| EP3960865A1 (en) | 2010-08-02 | 2022-03-02 | Regeneron Pharmaceuticals, Inc. | Mice that make binding proteins comprising vl domains |
| ME03732B (me) | 2011-02-25 | 2021-01-20 | Regeneron Pharma | Miševi s ADAM6 |
| US10040826B2 (en) | 2011-07-05 | 2018-08-07 | Duke University | Human immunodeficiency virus type 1 (HIV-1) N-terminal deleted GP120 immunogens |
| HRP20192255T1 (hr) * | 2011-08-05 | 2020-03-06 | Regeneron Pharmaceuticals, Inc. | Humanizirani miševi s univerzalnim lakim lancem |
| JP2014531452A (ja) | 2011-09-19 | 2014-11-27 | カイマブ・リミテッド | 動物、レパートリーおよび方法 |
| BR112014006390A2 (pt) | 2011-09-19 | 2017-03-28 | Kymab Ltd | anticorpos, domínios variáveis e cadeias feitos especialmente para uso humano |
| WO2013045916A1 (en) | 2011-09-26 | 2013-04-04 | Kymab Limited | Chimaeric surrogate light chains (slc) comprising human vpreb |
| CA2850745C (en) | 2011-10-03 | 2022-12-13 | Duke University | Vaccine |
| HRP20220253T1 (hr) | 2011-10-17 | 2022-04-29 | Regeneron Pharmaceuticals, Inc. | Miševi s ograničenim teškim lancem imunoglobulina |
| GB201122047D0 (en) * | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| US20180295821A1 (en) * | 2011-12-02 | 2018-10-18 | Kymab Limited | Transgenic Animals |
| ME03477B (me) | 2011-12-20 | 2020-01-20 | Regeneron Pharma | Miševi sa humanizovanim lakim lancem |
| SG10201913428QA (en) * | 2012-02-01 | 2020-03-30 | Regeneron Pharma | Humanized rodents that express heavy chains containing vl domains |
| PT2825037T (pt) | 2012-03-16 | 2019-08-07 | Regeneron Pharma | Animais não humanos que expressam sequências de imunoglobulinas sensíveis ao ph |
| RU2014141536A (ru) | 2012-03-16 | 2016-05-10 | Регенерон Фармасьютикалз, Инк. | Мыши, которые продуцируют антигенсвязывающие белки с зависимыми от величины ph характеристиками связывания |
| SMT201800395T1 (it) | 2012-03-16 | 2018-09-13 | Regeneron Pharma | Anticorpi a catena leggera ingegnerizzati con istidina e roditori modificati geneticamente per la generazione degli stessi |
| US20140013456A1 (en) | 2012-03-16 | 2014-01-09 | Regeneron Pharmaceuticals, Inc. | Histidine Engineered Light Chain Antibodies and Genetically Modified Non-Human Animals for Generating the Same |
| GB2502127A (en) * | 2012-05-17 | 2013-11-20 | Kymab Ltd | Multivalent antibodies and in vivo methods for their production |
| US10251377B2 (en) | 2012-03-28 | 2019-04-09 | Kymab Limited | Transgenic non-human vertebrate for the expression of class-switched, fully human, antibodies |
| DK2838917T3 (da) | 2012-04-20 | 2019-08-26 | Merus Nv | Fremgangsmåder og midler til frembringelse af heterodimere ig-lignende molekyler |
| KR102484480B1 (ko) * | 2012-06-12 | 2023-01-04 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 |
| HK1218866A1 (zh) | 2013-02-06 | 2017-03-17 | 瑞泽恩制药公司 | 基於b细胞谱系的人源化动物的免疫原设计 |
| LT2840892T (lt) * | 2013-02-20 | 2018-07-25 | Regeneron Pharmaceuticals, Inc. | Nežmogaus tipo gyvūnai su modifikuotomis imunoglobulino sunkiųjų grandinių sekomis |
| PL2967012T3 (pl) * | 2013-03-14 | 2021-04-19 | Erasmus University Medical Center Rotterdam | Transgeniczne ssaki inne niż człowiek do wytwarzania przeciwciał |
| WO2014141192A1 (en) * | 2013-03-15 | 2014-09-18 | Erasmus University Medical Center | Generation of heavy chain-only antibodies |
| US9788534B2 (en) | 2013-03-18 | 2017-10-17 | Kymab Limited | Animal models and therapeutic molecules |
| US9783618B2 (en) | 2013-05-01 | 2017-10-10 | Kymab Limited | Manipulation of immunoglobulin gene diversity and multi-antibody therapeutics |
| US11707056B2 (en) | 2013-05-02 | 2023-07-25 | Kymab Limited | Animals, repertoires and methods |
| US9783593B2 (en) | 2013-05-02 | 2017-10-10 | Kymab Limited | Antibodies, variable domains and chains tailored for human use |
| ES2993142T3 (en) | 2013-10-01 | 2024-12-23 | Kymab Ltd | Animal models and therapeutic molecules |
| JP6267986B2 (ja) * | 2014-02-13 | 2018-01-24 | 株式会社特殊免疫研究所 | ヒトの特定分子と結合する分子標的物質のｉｎｖｉｖｏ評価法 |
| BR112016021679A2 (pt) | 2014-03-21 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | proteína de ligação ao antígeno, métodos de produção de uma proteína de ligação ao antígeno e de identificação de uma ou mais proteínas de ligação ao antígeno, hibridoma, ácido nucleico, célula, e, animal não humano geneticamente modificado. |
| SG10201808225TA (en) | 2014-03-21 | 2018-10-30 | Regeneron Pharma | Non-human animals that make single domain binding proteins |
| WO2016044745A1 (en) | 2014-09-19 | 2016-03-24 | Regeneron Pharmaceuticals, Inc. | Chimeric antigen receptors |
| HK1250038A1 (zh) | 2015-03-19 | 2018-11-23 | 瑞泽恩制药公司 | 选择结合抗原的轻链可变区的非人动物 |
| TW202417497A (zh) | 2015-10-12 | 2024-05-01 | 美商再生元醫藥公司 | 活化瘦素受體的抗原結合蛋白 |
| EP3402326A1 (en) | 2016-01-13 | 2018-11-21 | Regeneron Pharmaceuticals, Inc. | Rodents having an engineered heavy chain diversity region |
| RU2018130010A (ru) | 2016-02-16 | 2020-03-17 | Регенерон Фармасьютикалз, Инк. | Животные, отличные от человека, имеющие мутантный ген кинурениназы |
| CN109475109B (zh) * | 2016-05-20 | 2021-10-29 | 瑞泽恩制药公司 | 用于使用多个引导rna来破坏免疫耐受性的方法 |
| SI3462853T1 (sl) | 2016-06-03 | 2023-05-31 | Regeneron Pharmaceuticals, Inc. | Glodavci, ki izražajo eksogeno terminalno deoksinukleotidiltransferazo |
| WO2017214089A1 (en) * | 2016-06-06 | 2017-12-14 | Regeneron Pharmaceuticals, Inc. | Non-human animals expressing antibodies with human lambda light chains |
| EP3766343B1 (en) | 2016-11-04 | 2022-05-11 | Regeneron Pharmaceuticals, Inc. | Non-human animals having an engineered immunoglobulin lambda light chain locus |
| US11122042B1 (en) | 2017-05-12 | 2021-09-14 | F5 Networks, Inc. | Methods for dynamically managing user access control and devices thereof |
| EP3635009B1 (en) | 2017-06-07 | 2026-02-25 | Regeneron Pharmaceuticals, Inc. | Compositions and methods for internalizing enzymes |
| LT3720279T (lt) | 2017-12-05 | 2022-10-25 | Regeneron Pharmaceuticals, Inc. | Pelės, turinčios sukonstruotą imunoglobulino lambda lengvąją grandinę, ir jų panaudojimas |
| IL276464B2 (en) | 2018-02-07 | 2026-01-01 | Regeneron Pharma | Methods and compositions for administering therapeutic protein |
| US20210000088A1 (en) | 2018-03-21 | 2021-01-07 | Crystal Bioscience Inc. | Transgenic chicken that produces human antibodies |
| HUE070158T2 (hu) | 2018-03-24 | 2025-05-28 | Regeneron Pharma | Genetikailag módosított egerek vagy patkányok peptid-mhc komplexek elleni terápiás antitestek létrehozásra, ezek elõállítására szolgáló módszerek, valamint alkalmazásuk |
| JP7328243B2 (ja) | 2018-03-26 | 2023-08-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 治療薬を試験するためのヒト化げっ歯類 |
| PT3773713T (pt) | 2018-04-06 | 2025-07-29 | Regeneron Pharma | Anticorpo agonista do recetor de leptina para usar no aumento da massa óssea num sujeito que sofre de disfunção metabólica ou de hipoleptinemia |
| MA52626A (fr) | 2018-05-17 | 2021-03-24 | Regeneron Pharma | Anticorps anti-cd63, conjugués et leurs utilisations |
| WO2019240999A1 (en) * | 2018-06-13 | 2019-12-19 | Crystal Bioscience Inc. | Camelization of a human variable domain by gene conversion |
| IL318469A (en) | 2018-06-14 | 2025-03-01 | Regeneron Pharma | Non-human animals capable of reorganizing transgenic DH-DH, and their uses |
| WO2020169022A1 (en) | 2019-02-18 | 2020-08-27 | Beijing Biocytogen Co., Ltd | Genetically modified non-human animals with humanized immunoglobulin locus |
| SG11202107589PA (en) | 2019-02-22 | 2021-08-30 | Regeneron Pharma | Rodents having genetically modified sodium channels and methods of use thereof |
| MX2021014893A (es) | 2019-06-05 | 2022-03-11 | Regeneron Pharma | Animales no humanos que tienen un repertorio de cadena ligera lambda limitado expresado a partir del locus kappa y usos de estos. |
| DK3785536T4 (da) | 2019-08-28 | 2025-10-27 | Trianni Inc | Adam6-knockin-mus |
| AU2020395122A1 (en) | 2019-12-02 | 2022-06-09 | Regeneron Pharmaceuticals, Inc. | Peptide-MHC II protein constructs and uses thereof |
| IL298632A (en) | 2020-06-02 | 2023-01-01 | Biocytogen Pharmaceuticals Beijing Co Ltd | Non-human animals genetically modified with a common light chain immunoglobulin locus |
| EP4211155A1 (en) | 2020-09-11 | 2023-07-19 | Regeneron Pharmaceuticals, Inc. | Identification and production of antigen-specific antibodies |
| CA3199879A1 (en) | 2020-12-16 | 2022-06-23 | Regeneron Pharmaceuticals, Inc. | Mice expressing humanized fc alpha receptors |
| JP2024501796A (ja) | 2020-12-23 | 2024-01-16 | リジェネロン・ファーマシューティカルズ・インコーポレイテッド | 膜貫通タンパク質に結合する抗体、および抗体を産生する細胞を取得する方法 |
| US20240317849A1 (en) | 2020-12-23 | 2024-09-26 | Regeneron Pharmaceuticals, Inc. | Nucleic acids encoding anchor modified antibodies and uses thereof |
| MX2023012300A (es) | 2021-04-20 | 2023-10-26 | Regeneron Pharma | Anticuerpos humanos contra artemina y metodos de uso de estos. |
| WO2024015816A1 (en) | 2022-07-12 | 2024-01-18 | Regeneron Pharmaceuticals, Inc. | Antibodies to ciliary neurotrophic factor receptor (cntfr) and methods of use thereof |
| KR20250150011A (ko) | 2023-02-13 | 2025-10-17 | 리제너론 파마슈티칼스 인코포레이티드 | 항-인간 cacng1 항체를 이용한 근육 관련 장애 치료 |
| AU2024265507A1 (en) | 2023-05-02 | 2025-10-30 | Regeneron Pharmaceuticals, Inc. | Anti-human m-cadherin (cdh15) antibodies, conjugates, and uses thereof for delivery of genetic payloads to muscle cells |
| CN121568720A (zh) | 2023-07-10 | 2026-02-24 | 瑞泽恩制药公司 | 抗人类cacng1抗体-药物缀合物及其用途 |
| WO2025055311A1 (zh) | 2023-09-15 | 2025-03-20 | 赛业（苏州）生物科技有限公司 | 用于制备抗体的基因修饰小鼠及其制备方法 |
| EP4548758A4 (en) * | 2023-09-15 | 2025-11-19 | Cyagen Biosciences Suzhou Inc | Genetically modified mice for antibody preparation and the method of preparation |
| WO2025064738A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Dntt 250-258 off-target peptides and uses thereof |
| WO2025064761A1 (en) | 2023-09-22 | 2025-03-27 | Regeneron Pharmaceuticals, Inc. | Kras10-18 g12d off-target peptides and uses thereof |
| EP4606901A1 (en) * | 2024-01-02 | 2025-08-27 | Gempharmatech Co., Ltd | Animal model for producing humanized antibody, and construction method therefor |
| WO2026006724A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Prame off-target peptides and uses thereof |
| WO2026006734A1 (en) | 2024-06-28 | 2026-01-02 | Regeneron Pharmaceuticals, Inc. | Off-target peptide-mhc complex conformation modeling systems and methods for antigen-recognition molecule development |
| WO2026030428A2 (en) | 2024-08-01 | 2026-02-05 | Regeneron Pharmaceuticals, Inc. | Prostate-specific antigen peptides and uses thereof |
| WO2026035843A2 (en) | 2024-08-06 | 2026-02-12 | Regeneron Pharmaceuticals, Inc. | Non-human animals having modified immunoglobulin heavy chain constant region locus and uses thereof |
Family Cites Families (47)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| GB8823869D0 (en) | 1988-10-12 | 1988-11-16 | Medical Res Council | Production of antibodies |
| WO1991000906A1 (en) | 1989-07-12 | 1991-01-24 | Genetics Institute, Inc. | Chimeric and transgenic animals capable of producing human antibodies |
| US6673986B1 (en) | 1990-01-12 | 2004-01-06 | Abgenix, Inc. | Generation of xenogeneic antibodies |
| US6657103B1 (en) | 1990-01-12 | 2003-12-02 | Abgenix, Inc. | Human antibodies derived from immunized xenomice |
| US7041871B1 (en) | 1995-10-10 | 2006-05-09 | Genpharm International, Inc. | Transgenic non-human animals capable of producing heterologous antibodies |
| KR100371784B1 (ko) * | 1992-12-01 | 2003-07-22 | 프로테인 디자인랩스, 인코포레이티드 | L-셀렉틴과반응성인인체화된항체 |
| EP2305027B1 (en) | 1996-12-03 | 2014-07-02 | Amgen Fremont Inc. | Transgenic mammals having human Ig loci including plural VH and Vkappa regions and antibodies produced therefrom |
| CN1203922A (zh) * | 1997-03-21 | 1999-01-06 | 三共株式会社 | 人源化抗人fas抗体 |
| US20020062010A1 (en) | 1997-05-02 | 2002-05-23 | Genentech, Inc. | Method for making multispecific antibodies having heteromultimeric and common components |
| RU10506U1 (ru) | 1999-04-08 | 1999-08-16 | Кривулин Виталий Николаевич | Ручной культиватор |
| CA2373638A1 (en) * | 1999-05-27 | 2000-12-07 | Human Genome Sciences, Inc. | Adam polynucleotides and polypeptides |
| GB0001448D0 (en) * | 2000-01-21 | 2000-03-08 | Novartis Ag | Organic compounds |
| US6586251B2 (en) | 2000-10-31 | 2003-07-01 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US7105348B2 (en) | 2000-10-31 | 2006-09-12 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| US6596541B2 (en) | 2000-10-31 | 2003-07-22 | Regeneron Pharmaceuticals, Inc. | Methods of modifying eukaryotic cells |
| PE20020574A1 (es) | 2000-12-06 | 2002-07-02 | Wyeth Corp | Anticuerpos humanizados que reconocen el peptido amiloideo beta |
| US7034134B2 (en) | 2001-04-26 | 2006-04-25 | Bristol-Myers Squibb Company | Polynucleotide encoding a novel metalloprotease highly expressed in the testis, MMP-29 |
| CN1789416B (zh) * | 2001-05-11 | 2011-11-16 | 协和发酵麒麟株式会社 | 含人抗体λ轻链基因的人类人工染色体 |
| US7473557B2 (en) | 2001-06-06 | 2009-01-06 | Regeneron Pharmaceuticals, Inc. | Method for targeting transcriptionally active loci |
| US20030108925A1 (en) | 2001-10-05 | 2003-06-12 | U.S. Epa | Genetic testing for male factor infertility |
| US20060199204A1 (en) | 2001-10-05 | 2006-09-07 | U.S. Epa | Genetic testing for male factor infertility |
| JP4099646B2 (ja) | 2002-06-04 | 2008-06-11 | 株式会社安川電機 | ボイスコイルモータ |
| PT2314629E (pt) | 2002-07-18 | 2014-01-22 | Merus B V | Produção recombinante de misturas de anticorpos |
| RU2251699C1 (ru) | 2003-09-25 | 2005-05-10 | Киселев Всеволод Иванович | Способ ранней и доклинической диагностики цервикального рака |
| AU2005295269B2 (en) | 2004-10-19 | 2010-05-13 | Regeneron Pharmaceuticals, Inc. | Method for generating an animal homozygous for a genetic modification |
| ATE416465T1 (de) | 2005-06-30 | 2008-12-15 | Borealis Tech Oy | Überzug-schicht für energie- oder kommunikationskabel |
| AU2007235496B2 (en) * | 2006-03-31 | 2013-11-21 | E. R. Squibb & Sons, L.L.C. | Transgenic animals expressing chimeric antibodies for use in preparing human antibodies |
| RS52176B (sr) | 2006-06-02 | 2012-08-31 | Regeneron Pharmaceuticals Inc. | Antitela visokog afiniteta prema humanom il-6 receptoru |
| JP5588866B2 (ja) | 2007-08-10 | 2014-09-10 | メダレックス エル．エル．シー． | Ｈｃｏ３２およびｈｃｏ２７、ならびに関連実施例 |
| US7659842B2 (en) | 2007-10-24 | 2010-02-09 | Infineon Technologies Ag | Quantization error reduction in PWM full-MASH converters |
| KR101987351B1 (ko) | 2008-09-30 | 2019-06-10 | 아블렉시스, 엘엘씨 | 키메라 항체의 제조를 위한 인간 이외의 포유동물 |
| RU2011129459A (ru) * | 2008-12-18 | 2013-01-27 | Эрасмус Юниверсити Медикал Сентр Роттердам | Трансгенные животные (не человек), экспрессирующие гуманизированные антитела, и их применение |
| GB0905023D0 (en) | 2009-03-24 | 2009-05-06 | Univ Erasmus Medical Ct | Binding molecules |
| JP5399140B2 (ja) * | 2009-06-18 | 2014-01-29 | 株式会社タイトー | モールス信号通信システム |
| CN102638971B (zh) | 2009-07-08 | 2015-10-07 | 科马布有限公司 | 动物模型及治疗分子 |
| WO2011072204A1 (en) | 2009-12-10 | 2011-06-16 | Regeneron Pharmaceuticals, Inc. | Mice that make heavy chain antibodies |
| US10143186B2 (en) | 2010-02-08 | 2018-12-04 | Regeneron Pharmaceuticals, Inc. | Common light chain mouse |
| US20120021409A1 (en) | 2010-02-08 | 2012-01-26 | Regeneron Pharmaceuticals, Inc. | Common Light Chain Mouse |
| AU2011266843C9 (en) | 2010-06-17 | 2018-03-01 | Kymab Limited | Animal models and therapeutic molecules |
| ME03732B (me) | 2011-02-25 | 2021-01-20 | Regeneron Pharma | Miševi s ADAM6 |
| HRP20192255T1 (hr) | 2011-08-05 | 2020-03-06 | Regeneron Pharmaceuticals, Inc. | Humanizirani miševi s univerzalnim lakim lancem |
| HRP20220253T1 (hr) | 2011-10-17 | 2022-04-29 | Regeneron Pharmaceuticals, Inc. | Miševi s ograničenim teškim lancem imunoglobulina |
| GB201118579D0 (en) | 2011-10-27 | 2011-12-07 | Micromass Ltd | Control of ion populations |
| GB201122047D0 (en) | 2011-12-21 | 2012-02-01 | Kymab Ltd | Transgenic animals |
| US9253965B2 (en) | 2012-03-28 | 2016-02-09 | Kymab Limited | Animal models and therapeutic molecules |
| ME03477B (me) | 2011-12-20 | 2020-01-20 | Regeneron Pharma | Miševi sa humanizovanim lakim lancem |
| KR102484480B1 (ko) | 2012-06-12 | 2023-01-04 | 리제너론 파마슈티칼스 인코포레이티드 | 제한된 면역글로불린 중쇄 유전자좌를 가지는 인간화된 비-인간 동물 |
-
2012
- 2012-02-24 ME MEP-2020-41A patent/ME03732B/me unknown
- 2012-02-24 HR HRP20230526TT patent/HRP20230526T1/hr unknown
- 2012-02-24 IN IN7629CHN2013 patent/IN2013CN07629A/en unknown
- 2012-02-24 ES ES12716101.6T patent/ES2532487T3/es active Active
- 2012-02-24 PT PT141549188T patent/PT2738258T/pt unknown
- 2012-02-24 FI FIEP12192727.1T patent/FI2578688T4/fi active
- 2012-02-24 EP EP22156414.9A patent/EP4067496B1/en active Active
- 2012-02-24 DK DK14154967.5T patent/DK2738259T3/da active
- 2012-02-24 SI SI201231712T patent/SI2738258T2/sl unknown
- 2012-02-24 ES ES22156414T patent/ES2946169T3/es active Active
- 2012-02-24 HU HUE12716101A patent/HUE024534T2/hu unknown
- 2012-02-24 ME MEP2019272 patent/ME03537B/xx unknown
- 2012-02-24 NZ NZ731926A patent/NZ731926A/en unknown
- 2012-02-24 EP EP20170540.7A patent/EP3744850A1/en active Pending
- 2012-02-24 SG SG10201913160QA patent/SG10201913160QA/en unknown
- 2012-02-24 DK DK14154918.8T patent/DK2738258T4/da active
- 2012-02-24 CN CN201610204885.6A patent/CN105861548B/zh active Active
- 2012-02-24 LT LTEP14154967.5T patent/LT2738259T/lt unknown
- 2012-02-24 US US13/404,075 patent/US8642835B2/en active Active
- 2012-02-24 WO PCT/US2012/026416 patent/WO2012141798A1/en not_active Ceased
- 2012-02-24 RS RS20150163A patent/RS53880B1/sr unknown
- 2012-02-24 EP EP14154967.5A patent/EP2738259B1/en active Active
- 2012-02-24 DK DK12716101.6T patent/DK2550363T3/en active
- 2012-02-24 DE DE14176593.3T patent/DE14176593T1/de active Pending
- 2012-02-24 DK DK12192727.1T patent/DK2578688T4/da active
- 2012-02-24 HU HUE12192727A patent/HUE046081T2/hu unknown
- 2012-02-24 FI FIEP14154918.8T patent/FI2738258T4/fi active
- 2012-02-24 SM SM20230173T patent/SMT202300173T1/it unknown
- 2012-02-24 DE DE14154967.5T patent/DE14154967T1/de active Pending
- 2012-02-24 RU RU2016109443A patent/RU2722373C2/ru not_active Application Discontinuation
- 2012-02-24 SI SI201231675T patent/SI2578688T2/sl unknown
- 2012-02-24 PL PL14154967T patent/PL2738259T3/pl unknown
- 2012-02-24 NZ NZ776770A patent/NZ776770A/en unknown
- 2012-02-24 LT LTEP14154918.8T patent/LT2738258T/lt unknown
- 2012-02-24 PT PT12716101T patent/PT2550363E/pt unknown
- 2012-02-24 SG SG10201913155QA patent/SG10201913155QA/en unknown
- 2012-02-24 SI SI201231739T patent/SI2738259T1/sl unknown
- 2012-02-24 KR KR1020137025191A patent/KR101387377B1/ko active Active
- 2012-02-24 PT PT221564149T patent/PT4067496T/pt unknown
- 2012-02-24 AU AU2012243291A patent/AU2012243291B2/en active Active
- 2012-02-24 RS RS20191599A patent/RS59661B2/sr unknown
- 2012-02-24 PT PT141549675T patent/PT2738259T/pt unknown
- 2012-02-24 DK DK14176593.3T patent/DK2813573T1/da unknown
- 2012-02-24 SM SM20200112T patent/SMT202000112T1/it unknown
- 2012-02-24 HU HUE14154967A patent/HUE047687T2/hu unknown
- 2012-02-24 SM SM20190581T patent/SMT201900581T1/it unknown
- 2012-02-24 EP EP14154918.8A patent/EP2738258B2/en active Active
- 2012-02-24 HR HRP20150262AT patent/HRP20150262T1/hr unknown
- 2012-02-24 BR BR112013021771-5A patent/BR112013021771B1/pt active IP Right Grant
- 2012-02-24 ES ES12192727T patent/ES2748832T5/es active Active
- 2012-02-24 PL PL12716101T patent/PL2550363T3/pl unknown
- 2012-02-24 ES ES14176593T patent/ES2805364T3/es active Active
- 2012-02-24 MX MX2016013717A patent/MX375115B/es unknown
- 2012-02-24 RU RU2013125717/10A patent/RU2582261C2/ru active
- 2012-02-24 SG SG2013064159A patent/SG192933A1/en unknown
- 2012-02-24 DE DE14154918.8T patent/DE14154918T1/de active Pending
- 2012-02-24 SI SI201232031T patent/SI4067496T1/sl unknown
- 2012-02-24 LT LT12192727T patent/LT2578688T/lt unknown
- 2012-02-24 PL PL14154918.8T patent/PL2738258T5/pl unknown
- 2012-02-24 MX MX2013009649A patent/MX343009B/es active IP Right Grant
- 2012-02-24 HU HUE22156414A patent/HUE062552T2/hu unknown
- 2012-02-24 ES ES14154967T patent/ES2770424T3/es active Active
- 2012-02-24 HR HRP20192311TT patent/HRP20192311T4/hr unknown
- 2012-02-24 ME MEP-2015-35A patent/ME02106B/me unknown
- 2012-02-24 JP JP2013550677A patent/JP2014507137A/ja active Pending
- 2012-02-24 CN CN201280010457.XA patent/CN103429746B/zh active Active
- 2012-02-24 DE DE12716101T patent/DE12716101T1/de active Pending
- 2012-02-24 SG SG10201405135RA patent/SG10201405135RA/en unknown
- 2012-02-24 HU HUE14154918A patent/HUE046746T2/hu unknown
- 2012-02-24 RS RS20191337A patent/RS59413B2/sr unknown
- 2012-02-24 HR HRP20191895TT patent/HRP20191895T4/hr unknown
- 2012-02-24 ES ES14154918T patent/ES2758974T5/es active Active
- 2012-02-24 RS RS20230475A patent/RS64280B1/sr unknown
- 2012-02-24 SI SI201230157T patent/SI2550363T1/sl unknown
- 2012-02-24 RS RS20200177A patent/RS59929B1/sr unknown
- 2012-02-24 PL PL22156414.9T patent/PL4067496T3/pl unknown
- 2012-02-24 PT PT121927271T patent/PT2578688T/pt unknown
- 2012-02-24 LT LTEP22156414.9T patent/LT4067496T/lt unknown
- 2012-02-24 MY MYPI2013003123A patent/MY172713A/en unknown
- 2012-02-24 DE DE12192727T patent/DE12192727T1/de active Pending
- 2012-02-24 EP EP12192727.1A patent/EP2578688B2/en active Active
- 2012-02-24 DK DK22156414.9T patent/DK4067496T5/da active
- 2012-02-24 EP EP14176593.3A patent/EP2813573B1/en active Active
- 2012-02-24 EP EP12716101.6A patent/EP2550363B1/en active Active
- 2012-02-24 PL PL12192727.1T patent/PL2578688T5/pl unknown
- 2012-02-24 SM SM20190744T patent/SMT201900744T1/it unknown
- 2012-02-24 CA CA2820824A patent/CA2820824A1/en not_active Withdrawn
-
2013
- 2013-05-09 US US13/890,519 patent/US8697940B2/en active Active
- 2013-06-04 IL IL226727A patent/IL226727A/en active IP Right Grant
- 2013-08-08 ZA ZA2013/05998A patent/ZA201305998B/en unknown
- 2013-08-21 MX MX2020009714A patent/MX2020009714A/es unknown
-
2014
- 2014-02-27 US US14/192,051 patent/US9932408B2/en active Active
- 2014-03-20 JP JP2014057616A patent/JP5866127B2/ja active Active
-
2015
- 2015-01-20 US US14/600,829 patent/US10072095B2/en active Active
- 2015-02-26 JP JP2015036588A patent/JP2015107131A/ja not_active Withdrawn
- 2015-03-03 CY CY20151100221T patent/CY1116301T1/el unknown
- 2015-03-11 SM SM201500061T patent/SMT201500061B/xx unknown
- 2015-04-09 US US14/682,859 patent/US9944716B2/en active Active
- 2015-10-07 AU AU2015238806A patent/AU2015238806A1/en not_active Abandoned
-
2016
- 2016-04-27 JP JP2016088848A patent/JP2016135143A/ja not_active Withdrawn
-
2017
- 2017-10-26 AU AU2017251802A patent/AU2017251802A1/en not_active Abandoned
-
2018
- 2018-06-04 JP JP2018107070A patent/JP2018143250A/ja not_active Withdrawn
- 2018-08-09 US US16/059,871 patent/US10577430B2/en active Active
- 2018-08-09 US US16/059,821 patent/US10905108B2/en active Active
- 2018-08-09 US US16/059,884 patent/US10694725B2/en active Active
- 2018-08-09 US US16/059,922 patent/US10905109B2/en active Active
- 2018-08-20 IL IL261243A patent/IL261243B/en active IP Right Grant
-
2019
- 2019-07-09 JP JP2019127562A patent/JP2019187446A/ja not_active Withdrawn
- 2019-08-13 IL IL268671A patent/IL268671B/en active IP Right Grant
- 2019-09-19 CY CY20191100988T patent/CY1122205T1/el unknown
- 2019-10-23 CY CY20191101104T patent/CY1122459T1/el unknown
-
2020
- 2020-01-22 CY CY20201100054T patent/CY1122820T1/el unknown
- 2020-02-21 HR HRP20200294TT patent/HRP20200294T1/hr unknown
- 2020-02-21 AU AU2020201279A patent/AU2020201279A1/en not_active Abandoned
- 2020-04-16 IL IL273986A patent/IL273986B/en active IP Right Grant
- 2020-12-21 US US17/129,706 patent/US12207628B2/en active Active
- 2020-12-21 US US17/129,708 patent/US11950578B2/en active Active
-
2022
- 2022-02-11 FI FIEP22156414.9T patent/FI4067496T3/fi active
- 2022-02-28 JP JP2022029501A patent/JP2022071051A/ja active Pending
- 2022-07-22 AU AU2022206806A patent/AU2022206806B2/en active Active
-
2023
- 2023-05-31 CY CY20231100256T patent/CY1126091T1/el unknown
-
2024
- 2024-03-06 US US18/597,797 patent/US20240306617A1/en active Pending
- 2024-12-05 JP JP2024212173A patent/JP2025032218A/ja active Pending
-
2025
- 2025-12-17 AU AU2025283466A patent/AU2025283466A1/en active Pending